Young Jonathan, Chief Operating Officer of Akero Therapeutics (AKRO), has demonstrated a clear selling bias in his recent insider transactions, with $1.8 million in total sales outweighing $1.1 million in purchases across 30 reported trades. His activity has been concentrated exclusively in AKRO shares, with the most significant disposals occurring in three clusters: a $444,027 sale on September 2, 2025, followed by a $263,750 acquisition and $597,000 in combined sales on October 1, then another $290,000 in purchases on November 24. The pattern shows disposition activity accelerating in late 2025, with six sales in the most recent period including a $395,398 transaction on October 1 and a $201,581 same-day sale. Notably, all December 2025 filings show derivative transactions with no reported value, while the November 24 buys—three separate purchases totaling approximately $290,000—represent the last outright equity acquisitions. The data reveals a shift from mixed buying and selling earlier in the period to exclusively non-purchase filings in December, though the derivative nature of those recent transactions makes their economic impact unclear without further disclosure.
AI-assisted summary